Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada

SAN DIEGO--()--Adamis Pharmaceuticals Corporation (OTCBB: ADMP), today announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada. Broad claims to a patent entitled “Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders” have been allowed. These include claims for the use of APC-100 to treat prostate cancer and for the use of APC-100 to prevent the occurrence or recurrence of prostate cancer. Notice of Allowance is the final step in the issuance of a patent. This patent will significantly strengthen Adamis’ patent portfolio for the use of APC-100 in the treatment of prostate cancer.

APC-100 is part of an ongoing Phase 1/2a clinical prostate study that began in August of this year. The study began at the University of Wisconsin Carbone Cancer Center and has recently been extended to Wayne State University Karmanos Cancer Institute. Both of these institutions are currently named within “The Prostate Cancer Clinical Trials Consortium.”

APC-100 has multiple modes of action. It is an orally available anti-androgenic/anti-inflammatory, signal transduction inhibitor drug. APC-100 has demonstrated to have higher therapeutic activity than the current marketed Standard of Care anti-androgens. Pre-clinical studies confirming the use of APC-100 for the treatment of prostate cancer were pioneered by Dr. George Wilding and his team. Dr. Wilding is the Assistant Dean for Oncology and Director of the University of Wisconsin Carbone Cancer Center. In addition to increasing time to tumor progression and survival, APC-100 also induced a significant decrease in PSA production. These and other characteristics make APC-100 a first-in-class compound for the potential treatment of both castrate-sensitive and castrate-resistant prostate cancer.

APC-100 has previously received the National Cancer Institute’s (NCI) multi-year, multi-million dollar RAPID Award (Rapid Access to Preventative Intervention Development). Each year, this award is given by the NCI Division of Cancer Prevention, under the RAPID Program (now called PREVENT), to what it believes are the most promising new preventative/therapeutic anti-cancer drugs.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations or future financial performance, including, but not limited to the following statements: the company’s beliefs concerning the safety and effectiveness of the compounds and drug product candidates described in this press release; the results of any future clinical trials that the company may conduct relating to the licensed compounds; the ability to fund future product development; future revenues expected from any of the licensed compounds, assuming that they are developed and approved for marketing by the FDA and other regulatory authorities; and the intellectual property protection that may be afforded by any patents or patent applications relating to the licensed technology. Statements in this press release concerning future milestone events depend on several factors beyond the company’s control, including receipt of adequate funding to support these activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http://www.sec.gov. Adamis expressly disclaims any intent to update any forward-looking statements.

Contacts

Capital Group Communications, Inc.
Mark Bernhard mark@capitalgc.com or
Mark Gundy mark.gundy@capitalgc.com
Tel: 415.332.7200

Contacts

Capital Group Communications, Inc.
Mark Bernhard mark@capitalgc.com or
Mark Gundy mark.gundy@capitalgc.com
Tel: 415.332.7200